TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06367322

Intervention type: DRUG
Intervention: Statin
Description: The primary objective of this study was to determine whether the use of statin has a protective effect against PEAP.~Patients undergoing ERCP for a specific medical indication were prospectively reviewed and the incidence of PEAP was compared according to whether or not the patients were receiving statin therapy.
Study: NCT04351659

Intervention type: OTHER
Intervention: Blood donation from convalescent donor
Description: Donation of 1 unit of blood or leukapheresis
Study: NCT00201799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: A total of 6 doses of Infliximab will be administered as follows:~Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42
Study: NCT00986349

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Liner
Description: 52 week treatment of EnoBarrier Liner
Study: NCT03039621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: For oral use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For oral use.
Study: NCT02342093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30EE+DRSP
Description: Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
Study: NCT00761215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 200 mg
Description: oral TR-701 200 mg for 5 to 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 300 mg
Description: oral TR-701 300 mg for 5 to 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 400 mg
Description: TR-701 400 mg for 5 to 7 days
Study: NCT00655720

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infant formula
Description: 1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula
Description: 1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant formula
Description: 1. hydrolyzed infant formula without probiotics~2. hydrolyzed infant formula with probiotics~3. hydrolyzed infant formula with probiotics
Study: NCT03577990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Technology Enhanced Coaching (ITEC)
Description: As participants wear the activity tracker, take their BP and weight, along with input of food intake and medication-taking, data is transmitted in real time via Bluetooth Smart technology to the Fitbit Plus dashboard. All data is tracked, analyzed, and transparently displayed for participants to view and better understand their condition, and actively engage in self-care. Staff monitor data and communicate with participants to encourage active engagement in action plans by sending tailored coaching messages (ITEC) via the Fitbit Plus dashboard to the treatment arm weekly for 3 months, and biweekly for 3 months to motivate and support (BP control, medication adherence, and lifestyle modifications). After 6 months, the treatment arm will be monitored an additional 3 months with no tailored coaching for sustainability.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Technology-No Coaching (IT)
Description: After receiving usual care for 3 months, the control arm will receive the same electronic monitoring as the treatment arm and data will be captured in the same manner with the Fitbit Plus dashboard. Participants will be expected to use the information from the dashboard and the CDSMP workshop as a guide to self-care without coaching (IT). Staff will only monitor data. Control participants will not be contacted between repeated measures data collection periods, except to send reminders if they are not participating daily.
Study: NCT01663441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL201
Description: mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL201
Description: mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL201
Description: mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NL201
Description: mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NL201
Description: The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NL201
Description: The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIL-11
Description: rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhIL-11
Description: rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
Study: NCT02215681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Study: NCT02596776

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat biopsy
Description: up to 16 biopsy samples will be taken from each subject

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fat biopsy
Description: up to 16 biopsy samples will be taken from each subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat biopsy
Description: up to 16 biopsy samples will be taken from each subject
Study: NCT03180372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Fractional Laser
Description: Consecutive and coincident fractional 2940 nm and 1470 nm lasers
Study: NCT01276652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Environmental modification
Description: Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
Study: NCT03394573

Intervention type: OTHER
Intervention: OCT guided treatment arm
Description: Intravitreal injection of Aflibercept for DME OCT guided
Study: NCT02554032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Innominate artery cannulation
Description: After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
Study: NCT01599728

Intervention type: DRUG
Group type: OTHER
Intervention: Urocortin 2, Urocortin 3 and Substance P
Description: After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones.

Intervention type: DRUG
Group type: OTHER
Intervention: Urocortin 2, Urocortin 3 and Substance P
Description: After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min \[15, 50 and 150 ng/min\] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) \[to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively\] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]) will be administered intra-arterially.~Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones.
Study: NCT00620711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olympic Cool Cap
Description: Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
Study: NCT01470560

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Description: Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Yoga Group
Description: Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
Study: NCT01472848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 05212389 or placebo
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 05212389 or placebo
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 05212389 or placebo
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
Study: NCT03394573

Intervention type: OTHER
Intervention: VA guided treatment arm
Description: Intravitreal injection of Aflibercept for DME VA guided
Study: NCT02596776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol and fat biopsy
Description: subset of subjects will receive propranolol and have fat biopsy performed
Study: NCT01472848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 05212389 or placebo
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
Study: NCT02596776

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: heavy water and fat biopsy
Description: subset of subjects will be given heavy water and have fat biopsy performed
Study: NCT01472848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF 05212389 or placebo
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF 05212389 or placebo
Description: QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
Study: NCT03655028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rhythmically auditory stimulation enhanced music
Description: Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program
Study: NCT03059615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerofe
Description: Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
Study: NCT01041092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: raloxifene
Description: Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
Study: NCT02830802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dr. Hauschka Med Mundspüllösung Salbei / cosmetics
Description: Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.~For an application fill the closure cap with the mouthwash.
Study: NCT04095520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Etching
Description: Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Etching
Description: Before the restorations, cavities will be etched Er:Cr YSGG laser with 4W output power, water pressure 95% and air pressure 60% with MGG6 tip with the spot size of 600 µm will be used.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phosphoric acid etching
Description: Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phosphoric acid etching
Description: Before the restorations, cavities will be etched with %37 phosphoric acid for 15 seconds.
Study: NCT03866200

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol
Description: 125 mg/day or 5 ml once per day for 90 days
Study: NCT03059615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
Study: NCT00811655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Surgery of a single brain metastasis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Pre-operative single fraction SRS
Study: NCT00747565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis ZM900 Multifocal Intraocular Lens
Description: Investigational intraocular lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CeeOn 911A monofocal IOL
Description: Monofocal Control IOL
Study: NCT03874715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart SAR341402
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study: NCT03603704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT02692079

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-PRF
Description: Flap Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allograft
Description: Flap Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allograft
Description: Flap Surgery
Study: NCT00523575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cubitan
Description: 400 ml/d
Study: NCT02680275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dead Sea Peloid Gel
Description: intravaginally
Study: NCT00421993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide
Description: Topical Gel, One application daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene
Description: Topical Gel,One application daily in the evening for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzoyl Peroxide
Description: Topical Gel, one application daily in the evening for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Gel Vehicle
Description: Topical Gel Vehicle,one application daily in the evening for 12 weeks
Study: NCT03362320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double layer fixation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single layer fixation
Study: NCT01819662

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced standard management
Description: Echocardiogram followed by letter to GP about results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimised heart failure management
Description: Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard management
Description: Usual care
Study: NCT03509090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block
Description: erector spinae block will be performed in this group as postoperative analgesia treatment.
Study: NCT03874715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine U100
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study: NCT03509090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: patients will receive only multimodal analgesic treatment including patient-controlled analgesia
Study: NCT03205631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Natural Frequency Patch
Description: Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Natural Frequency Patch
Description: Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
Study: NCT03275922

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo ZNS
Description: Placebo Zolmitriptan Nasal Spray
Study: NCT03874715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine U100
Description: Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Study: NCT03197415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma
Description: intradiscal injection of plasma-rich platelet
Study: NCT01308164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD Logic Pump Advisor
Description: Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor